Enric Rello Condomines
Director of Finance/CFO bij ORYZON GENOMICS S.A.
Profiel
Enric Rello Condomines is currently the Chief Operating & Financial Officer at Oryzon Genomics SA. He is also a Professor at Universitat Abat Oliba CEU.
Previously, he worked as the Finance Director at Sandoz Industrial Products SA from 1993 to 2007.
Dr. Rello Condomines completed his undergraduate degree at the University of Barcelona and holds undergraduate, graduate, and doctorate degrees from Universitat Abat Oliba CEU.
Actieve functies van Enric Rello Condomines
| Bedrijven | Functie | Begin |
|---|---|---|
| ORYZON GENOMICS S.A. | Director of Finance/CFO | 01-05-2011 |
| Universitat Abat Oliba CEU | Corporate Officer/Principal | - |
Eerdere bekende functies van Enric Rello Condomines
| Bedrijven | Functie | Einde |
|---|---|---|
Sandoz Industrial Products SA
 Sandoz Industrial Products SA Pharmaceuticals: MajorHealth Technology Sandoz Industrial Products SA engages in the manufacture and commercialization of pharmaceutical products. These include generic drugs, anti-infectives, and biosimilars for the treatment of cardiovascular, gastrointestinal, respiratory, and hematological conditions. The company was founded in 1966 and is headquartered in Palafolls, Spain. | Director of Finance/CFO | 01-01-2007 |
Opleiding van Enric Rello Condomines
| University of Barcelona | Undergraduate Degree |
| Universitat Abat Oliba CEU | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ORYZON GENOMICS S.A. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Sandoz Industrial Products SA
Sandoz Industrial Products SA Pharmaceuticals: MajorHealth Technology Sandoz Industrial Products SA engages in the manufacture and commercialization of pharmaceutical products. These include generic drugs, anti-infectives, and biosimilars for the treatment of cardiovascular, gastrointestinal, respiratory, and hematological conditions. The company was founded in 1966 and is headquartered in Palafolls, Spain. | Health Technology |
